JLE

Journal de Pharmacie Clinique

MENU

Highlights of the 2018 ISPOR conference Volume 38, issue 4, Décembre 2019

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4

  • Figure 5

  • Figure 6

Tables

Authors
1 Pôle de Santé Publique, Service d’évaluation économique en santé, Hospices civils de Lyon, Lyon, France ; Université Claude Bernard Lyon 1, Hesper EA 7425, Lyon, France
2 Pôle de pharmacie, Site Groupe Hospitalier Sud, CHU Bordeaux, Bordeaux, France
3 Unité de recherche médico-économique, CHU de Montpellier, Montpellier, France
4 Pôle pharmacie et stérilisation, Hôpital Pasteur 2, CHU de Nice, Nice, France
5 Département de pharmacie clinique, Hôpital universitaire Gustave Roussy, Villejuif, France
6 Service de pharmacie-stérilisation, Hôpitaux universitaires de Strasbourg et Laboratoire HuManiS (EA 7308), Strasbourg, France
7 Service de pharmacie, Grand Hôpital de l’Est Francilien, Meaux, France
* Correspondance

The 2018 congress of the ISPOR Europe (International society for pharmacoeconomics and outcomes research) was held in Barcelona from 10 to 14 November 2018. A group of pharmacists, physicians and health economists attended the conference and reported some of the highlights. They have gathered some of the different outcomes and chosen to present them in four different paragraphs: What are the roles of health policies on the penetration of biosimilars in Europe? Informal care, too often omitted from medico-economic studies, The French programme for medico-economic research (PRME) and health economists in the face of lay audience.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License